Novartis AG

Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors (2020) Pinter A, Kokolakis G, Rech J, Biermann MH, Häberle BM, Multmeier J, Reinhardt M Journal article Measurement of Skeletal Muscle Fiber Contractility with High-Speed Traction Microscopy (2020) Rausch M, Böhringer D, Steinmann M, Schubert DW, Schrüfer S, Mark C, Fabry B Journal article Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies (2019) Coates LC, Wallman JK, McGonagle D, Schett G, McInnes IB, Mease PJ, Rasouliyan L, et al. Journal article Psoriatic Arthritis - Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis (2019) Rech J, Sticherling M, Biermann M, Haeberle B, Reinhardt M Conference contribution Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES (2019) Schett G, Baraliakos X, Van Den Bosch F, Deodhar A, Gensler LS, Ostergaard M, Agawane S, et al. Conference contribution Psychiatric disorders are common comorbidities in patients with chronic spontaneous or inducible urticaria in Germany (2019) Weller K, Maurer M, Bauer A, Wedi B, Wagner N, Schliemann S, Baeumer D, et al. Conference contribution Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial (2019) Tahir H, Mease PJ, Kavanaugh A, Reimold A, Rech J, Hall S, Geusens P, et al. Conference contribution Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials (2019) Yao J, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, Van Cutsem E, et al. Journal article Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma (2019) Van Herpen CM, Agarwala SS, Hauschild A, Berking C, Thaddeus Beck J, Schadendorf D, Jansen R, et al. Journal article